Multilevel regression models of anxiety over the course of clinical treatment. by David H. Rosmarin (16542340)

Subjects:

Violin plots of the best fit modelled distributions of times to clinical outcome over the course of the pandemic for category A. by Thomas Ward (688068)

Subjects:

Data for subjects with significant slopes (regional progression or recovery colour coded, non-significant regions white) for the 4 data types over the study period. by Faran Sabeti (6166766)

Subjects:

Clinical course of patient no. by Kazuyoshi Ohkawa (836847)

Comparison of clinical indices among clinical courses. by Jun Sugihara (11690045)

Subjects:

Changes in the monthly contamination rate (per set) in blood culture (BC). by Miki Doi (15347878)

Subjects:

Descriptive statistics based on type of therapy and time of assessment. by Nina Brkić-Jovanović (18886883)

Subjects:

Scheffe post-hoc. by Nina Brkić-Jovanović (18886883)

Subjects:

MANCOVA’s main and interactive effect results. by Nina Brkić-Jovanović (18886883)

Subjects:

Interactive effect of time and type of therapy on divided attention measure. by Nina Brkić-Jovanović (18886883)

Subjects:

Bivariate correlation between age, education level, duration of the therapy and neurocognitive measures. by Nina Brkić-Jovanović (18886883)

Subjects:

S1 File - by Nina Brkić-Jovanović (18886883)

Subjects:

Species richness decreases significantly with increasing percent disturbance. by Catherine L. Cardelús (6429320)

Demographical and clinical characteristics of patients according to mortality. by Hasan Selcuk Ozger (11785143)

Subjects:

Weights did not vary significantly during PPS treatment. by Penny A. Rudd (10298691)

Evaluation of changes in some cytokine levels in survivor and non-survivor groups. by Hasan Selcuk Ozger (11785143)

Subjects:

The course, severity, and clinical management of MS-SAB. by Klaus Kessel (18591866)

Time course of best-corrected visual acuity (BCVA) in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

“…<p>In the recurrence group, BCVA (logMAR ± standard deviation) showed no significant change from baselines (0.37 ± 0.20) to 0.35 ± 0.23, 0.35 ± 0.18, 0.31 ± 0.23, 0.34 ± 0.26, 0.28 ± 0.30, and 0.24 ± 0.23 at 1, 3, 6, 12, 24, and 36 months, respectively (Kruskal–Wallis test, P = 0.45). …”

Total tau levels are significantly decreased in the healthy older brains compared to the younger brains. by Shreyasi Chatterjee (3531506)

Synaptopathy at IHC-SGN synapses decreases the peak of the CAP significantly, without changes to peak latency and width. by Maral Budak (6680351)